Condition: Breast Cancer · HR-positive Breast Cancer · Advanced Breast Cancer · Sponsor: West German Study Group
This is a multicentre phase-III-trial to evaluate the use of capivasertib in patients with HR+/HER2- advanced breast cancer and progression on prior endocrine-based treatment. The goal of this study is 1. To evaluate benefit of capivasertib regarding time to next treatment (TTNT1) - i.e., time "on treatment" with capivasertib. 2. To evaluate the benefits of patient reported outcome(PRO)-adherence regarding the deterioration of quality of life (DQoL)-free interval. There is no active comparison group but a historical control group consisting of data of patients treated within the CAPItello-291-study.. Participants will take capivasertib accompanied by standard of care endocrine treatment and are asked to document ther quality of life on standardised questionnaires. Optionally, patients can use eHealth support via their own smart phones.
This description comes directly from the study's public registry record.
Rico Laage, Dr. · 02161566230 · rico.laage@wsg-online.com
Always discuss trial participation with your own doctor first.
| Institut Jules Bordet | Anderlecht, Belgium | Not Yet Recruiting |
| CHC MontLegia | Liège, Belgium | Not Yet Recruiting |
| St. Elisabeth-Krankenhaus GmbH, Brustzentrum - Senologie | Cologne, North Rhine-Westphalia, Germany | Not Yet Recruiting |
| Universitätsklinikum Essen | Essen, North Rhine-Westphalia, Germany | Not Yet Recruiting |
| Brustzentrum Niederrhein, Johanniter Bethesda Krankenhaus | Mönchengladbach, North Rhine-Westphalia, Germany | Recruiting |
| Universitätsklinikum Münster AöR Brustzentrum | Münster, North Rhine-Westphalia, Germany | Not Yet Recruiting |
| Champalimaud Clinical Centre | Lisbon, Portugal | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07281833